LexDanaLexDanabeta
Inventor

Adam D. Hughes

Inventor
Belmont, CA, US

Overview

119→
Patents
2006–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 119 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
C07DHeterocyclic compounds27%
A61KPreparations for medical, dental or toiletry purposes24%
C07CAcyclic or carbocyclic compounds9%
C07BGeneral methods of organic chemistry3%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
C30BSingle-crystal growth1%
Y02PClimate change mitigation technologies in the production or processing of goods1%
A01NPreservation of bodies of humans or animals or plants or parts thereof0%
PatentTitleYear
10,836,744Diamide compounds having muscarinic receptor antagonist and b2 adrenergic receptor agonist activity202010,829,438Neprilysin inhibitors202010,759,813Neprilysin inhibitors202010,752,599Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof202010,744,104Neprilysin inhibitors202010,590,107Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity202010,570,120Neprilysin inhibitors202010,548,879(2R,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid202010,472,335Crystalline(2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof201910,358,433Diamide compounds having muscarinic receptor antagonist and b2 adrenergic receptor agonist activity201910,336,773Neprilysin inhibitors201910,315,984Neprilysin inhibitors201910,189,823Neprilysin inhibitors201910,172,834(2R,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid201910,138,220Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity201810,130,642Neprilysin inhibitors201810,123,984Neprilysin inhibitors201810,100,021Crystalline(2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof201810,053,417Neprilysin inhibitors201810,005,740Neprilysin inhibitors20189,981,999Neprilysin inhibitors20189,975,875Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity20189,884,807'Neprilysin inhibitors'20189,873,696Neprilysin inhibitors20189,872,855(2R,4R)-5-(5'-Chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid20189,873,685Neprilysin inhibitors20189,868,698'(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid'20189,845,332Neprilysin inhibitors20179,840,460'Neprilysin inhibitors'20179,839,639'Neprilysin inhibitors'20179,828,367Neprilysin inhibitors20179,783,507'Neprilysin inhibitors'20179,771,350'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20179,771,337'Neprilysin inhibitors'20179,724,359'Neprilysin inhibitors'20179,725,448'Neprilysin inhibitors'20179,688,692'Neprilysin inhibitors'20179,688,616'Neprilysin inhibitors'20179,682,957'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20179,682,052'Neprilysin inhibitors'20179,683,002'Neprilysin inhibitors'20179,670,140'Neprilysin inhibitors'20179,670,143'(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxmethyl-2-methylpentanoic acid'20179,670,186'Neprilysin inhibitors'20179,593,110'Neprilysin inhibitors'20179,585,882'Neprilysin inhibitors'20179,572,802'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20179,555,041'Neprilysin inhibitors'20179,533,962'(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid'20179,499,487'Neprilysin inhibitors'20169,487,514'Neprilysin inhibitors'20169,433,598'(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid'20169,428,457'Neprilysin inhibitors'20169,422,245'Neprilysin inhibitors'20169,394,275'Diamide compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity'20169,388,145'Neprilysin inhibitors'20169,334,245'Neprilysin inhibitors'20169,150,500'Neprilysin inhibitors'20159,126,956'Neprilysin inhibitors'20159,120,758'Neprilysin inhibitors'20159,120,747'Neprilysin inhibitors'20159,108,934'Neprilysin inhibitors'20159,096,496'Neprilysin inhibitors'20159,045,443'Nitric oxide donor neprilysin inhibitors'20159,000,173'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20158,993,752'Neprilysin inhibitors'20158,969,571'Biphenyl derivatives'20158,901,169'Neprilysin inhibitors'20148,871,792'Neprilysin inhibitors'20148,853,255'3-phenoxymethylpyrrolidine compounds'20148,853,427'Neprilysin inhibitors'20148,846,913'Neprilysin inhibitors'20148,816,088'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20148,691,868'Neprilysin inhibitors'20148,686,184'Neprilysin inhibitors'20148,618,131'Biphenyl derivatives'20138,586,536'Neprilysin inhibitors'20138,563,512'Neprilysin inhibitors'20138,551,978'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20138,513,244'Neprilysin inhibitors'20138,481,044'Neprilysin inhibitors'20138,455,665'3-phenoxymethylpyrrolidine compounds'20138,449,890'Neprilysin inhibitors'20138,399,488'Biphenyl compounds useful as muscarinic receptor antagonists'20138,273,786'3-phenoxymethylpyrrolidine compounds'20128,143,277'Method of using compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity'20128,138,345'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20128,134,006'Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity'20128,119,796'Biphenyl compounds useful as muscarinic receptor antagonists'20128,080,565'Substituted 4-amino-benzylpiperidine compounds'20118,013,152'Biphenyl compounds useful as muscarinic receptor antagonists'20118,008,278'Diarylmethyl and related compounds'20117,994,209'3-phenoxymethylpyrrolidine compounds'20117,893,256'Azabicycloalkane compounds'20117,879,879'Biphenyl derivatives'20117,829,583'Biphenyl derivatives'20107,829,728'Diarymethyl and related compounds'20107,732,441'Azabicycloalkane compounds'20107,728,144'Biphenyl compounds useful as muscarinic receptor antagonists'20107,687,521'Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity'20107,638,639'Substituted pyrrolidine and related compounds'20097,615,566'Substituted pyrrolidine and related compounds'20097,569,586'Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity'20097,524,965'Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity'20097,524,959'Biphenyl derivatives'20097,524,880'Crystalline form of a substituted pyrrolidine compound'20097,521,561'Biphenyl derivatives'20097,514,558'Biphenyl derivatives'20097,507,751'Biphenyl derivatives'20097,368,463'Substituted 4-amino-1-benzylpiperidine compounds'20087,358,244'Azabicycloalkane compounds'20087,355,046'Biphenyl derivatives'20087,351,718'Substituted pyrrolidine and related compounds'20087,351,717'Substituted pyrrolidine and related compounds'20087,345,175'Biphenyl derivatives'20087,317,102'Diarylmethyl and related compounds'20087,285,564'Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds'20077,183,292'Substituted pyrrolidine and related compounds'20077,141,671'Biphenyl derivatives'2006

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2006–2014Patents assigned to THERAVANCE INC (48)· patent assignee history
2006–2020Based in Belmont, CA, US· patent location history
2007–2011Based in San Francisco, CA, US· patent location history
2012–2017Patents assigned to HUGHES ADAM D (35)· patent assignee history
2012–2017Patents assigned to FLEURY MELISSA (26)· patent assignee history
2013–2017Patents assigned to GENDRON ROLAND (19)· patent assignee history
2016–2020Patents assigned to THERAVANCE BIOPHARMA R&D IP LLC (47)· patent assignee history
2016–2020Based in Half Moon Bay, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
THERAVANCE INC482006–2014
THERAVANCE BIOPHARMA R&D IP LLC472016–2020
HUGHES ADAM Dself352012–2017
FLEURY MELISSA262012–2017
GENDRON ROLAND192013–2017
Locations
LocationPatentsSpan
Belmont, California, US702006–2020
Half Moon Bay, California, US372016–2020
San Francisco, California, US122007–2011